drugset / Trial / NCT00002625

Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

NCT00002625

Phase 1 Completed 5 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of topotecan and radiation therapy in treating patients who have solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells.

Timeline

Start
1995-03
Primary completion
2000-04
Completion
2000-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Topotecan Small molecule 0.2 mg/m2 Intravenous
Subject Topotecan Small molecule 0.3 mg/m2 Intravenous
Subject Topotecan Small molecule 0.4 mg/m2 Intravenous
Subject Topotecan Small molecule 0.5 mg/m2 Intravenous